Pfizer Inc

PFE-N

NYSE:PFE

38.54
0.32 (0.84%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
HOLD
HOLD
December 3, 2018
Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade.
Pfizer Inc (PFE-N)
December 3, 2018
Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$45.990
Owned
Yes
PAST TOP PICK
PAST TOP PICK
November 22, 2018
(A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative.
Pfizer Inc (PFE-N)
November 22, 2018
(A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative.
Robert Lauzon
Deputy Chief Investment Officer, Middlefield Capital Corporation
Price
$0.000
Owned
Yes
DON'T BUY
DON'T BUY
October 29, 2018

A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead.

Pfizer Inc (PFE-N)
October 29, 2018

A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead.

Don Lato
President, Padlock Investment Management
Price
$43.230
Owned
No
HOLD
HOLD
August 23, 2018

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.

Pfizer Inc (PFE-N)
August 23, 2018

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.

Don Lato
President, Padlock Investment Management
Price
$42.200
Owned
No
DON'T BUY
DON'T BUY
August 7, 2018

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

Pfizer Inc (PFE-N)
August 7, 2018

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$40.840
Owned
No
PAST TOP PICK
PAST TOP PICK
July 25, 2018

(A Top Pick May 31/17 Up 20%) A stable, old-school pharma company. They can still spin out some businesses and they have a lot good projects in the pipeline.

Pfizer Inc (PFE-N)
July 25, 2018

(A Top Pick May 31/17 Up 20%) A stable, old-school pharma company. They can still spin out some businesses and they have a lot good projects in the pipeline.

Michael Simpson, CFA
Senior Vice-President, Sentry Investments
Price
$37.990
Owned
Yes
BUY
BUY
July 5, 2018

140 drugs that generate over $100 million in revenues. They have a good pipeline. Some interesting data on pain medication. Consistent revenue. Great valuation. There is no reason why this company shouldn’t be trading at 14 times earnings and it is trading at 11.5x. he expects a multiple expansion.

Pfizer Inc (PFE-N)
July 5, 2018

140 drugs that generate over $100 million in revenues. They have a good pipeline. Some interesting data on pain medication. Consistent revenue. Great valuation. There is no reason why this company shouldn’t be trading at 14 times earnings and it is trading at 11.5x. he expects a multiple expansion.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$36.870
Owned
Yes
PAST TOP PICK
PAST TOP PICK
May 29, 2018

(A Top Pick June 16/17, Up 12% ) Likes pharma and owns a couple of them. The time to buy is when they are facing a patent clift, and their biggest drugs are coming off-patents and the company has to find new drugs or buy other promising companies. Pfizer was one of those when they bought Wyeth. They have a big consumer products division, which provides lots of cash flow, good earnings but not huge growth, which they put up for sell recently but couldn’t really find a buyer. Still likes it longer term.

Pfizer Inc (PFE-N)
May 29, 2018

(A Top Pick June 16/17, Up 12% ) Likes pharma and owns a couple of them. The time to buy is when they are facing a patent clift, and their biggest drugs are coming off-patents and the company has to find new drugs or buy other promising companies. Pfizer was one of those when they bought Wyeth. They have a big consumer products division, which provides lots of cash flow, good earnings but not huge growth, which they put up for sell recently but couldn’t really find a buyer. Still likes it longer term.

Norman Levine
Managing Director, Portfolio Management Corp
Price
$35.700
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
April 27, 2018

(A Top Pick September 5/17 Up 12%) He still likes this, including the close to 4% yield. It is probably the “bluest” blue chip out there in the health sector.

Pfizer Inc (PFE-N)
April 27, 2018

(A Top Pick September 5/17 Up 12%) He still likes this, including the close to 4% yield. It is probably the “bluest” blue chip out there in the health sector.

David Dietze
Founder, Pres. & Chief Investment Strategist, Point View Wealth Management
Price
$37.000
Owned
Yes
DON'T BUY
DON'T BUY
April 25, 2018

He's gone the biotech route in the drug sector. Over the years, he has owned the big pharmas, but their growth has stagnated with growth in earnings done through cost containment--and you can't cut forever. Topline growth is better which is where he looks first in a stock. Pfizer hasn't had this.

Pfizer Inc (PFE-N)
April 25, 2018

He's gone the biotech route in the drug sector. Over the years, he has owned the big pharmas, but their growth has stagnated with growth in earnings done through cost containment--and you can't cut forever. Topline growth is better which is where he looks first in a stock. Pfizer hasn't had this.

Gordon Reid
President, GoodReid Investment Counsel
Price
$36.680
Owned
No
DON'T BUY
DON'T BUY
April 9, 2018

It's trading where it was 20 years ago, as with many large US drug stocks, due to tough FDA approval. He's very cautious in this sector. All countries are struggling with rising health costs.

Pfizer Inc (PFE-N)
April 9, 2018

It's trading where it was 20 years ago, as with many large US drug stocks, due to tough FDA approval. He's very cautious in this sector. All countries are struggling with rising health costs.

Lorne Steinberg
President & Portfolio Manager, Lorne Steinberg Wealth Management Inc
Price
$35.460
Owned
Unknown
BUY
BUY
March 21, 2018

Teva or Pfizer? He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

Pfizer Inc (PFE-N)
March 21, 2018

Teva or Pfizer? He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$36.270
Owned
Unknown
BUY
BUY
March 13, 2018

Likes healthcare. Boasts a 3.7% yield that'll likely increase, decent cash flow and growth. Company could spin-off.

Pfizer Inc (PFE-N)
March 13, 2018

Likes healthcare. Boasts a 3.7% yield that'll likely increase, decent cash flow and growth. Company could spin-off.

Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$36.750
Owned
No
COMMENT
COMMENT
March 8, 2018

Like many of the other major pharma companies has gone through their patent cliffs. It is trading at an attractive multiple and has an attractive dividend yield. She prefers Johnson & Johnson (JNJ-O).

Pfizer Inc (PFE-N)
March 8, 2018

Like many of the other major pharma companies has gone through their patent cliffs. It is trading at an attractive multiple and has an attractive dividend yield. She prefers Johnson & Johnson (JNJ-O).

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$36.770
Owned
No
COMMENT
COMMENT
February 14, 2018

Likes healthcare, but he has a tough time with drug companies. It takes a long time to get a patent with lots of research. Pfzier, though, has legacy, long-term drugs to draw on. This is an income vehicle. Doesn't expect new products right now. An income, not a growth play.

Pfizer Inc (PFE-N)
February 14, 2018

Likes healthcare, but he has a tough time with drug companies. It takes a long time to get a patent with lots of research. Pfzier, though, has legacy, long-term drugs to draw on. This is an income vehicle. Doesn't expect new products right now. An income, not a growth play.

Zachary Curry
Chief Operating Officer & Portfolio Manager, Davis-Rea Ltd.
Price
$35.190
Owned
Unknown
Showing 31 to 45 of 667 entries